Your browser doesn't support javascript.
loading
The evolutionary safety of mutagenic drugs should be assessed before drug approval.
Lobinska, Gabriela; Tretyachenko, Vyacheslav; Dahan, Orna; Nowak, Martin A; Pilpel, Yitzhak.
Afiliación
  • Lobinska G; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Tretyachenko V; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Dahan O; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
  • Nowak MA; Department of Mathematics & Department of Organismic and Evolutionary Biology, Harvard University, Cambridge, Massachusetts, United States of America.
  • Pilpel Y; Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel.
PLoS Biol ; 22(3): e3002570, 2024 Mar.
Article en En | MEDLINE | ID: mdl-38489394
ABSTRACT
Some drugs increase the mutation rate of their target pathogen, a potentially concerning mechanism as the pathogen might evolve faster toward an undesired phenotype. We suggest a four-step assessment of evolutionary safety for the approval of such treatments.
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Mutágenos Idioma: En Año: 2024 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Aprobación de Drogas / Mutágenos Idioma: En Año: 2024 Tipo del documento: Article